Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 3:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 882 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Period C Clear all
Not listed Not applicable Interventional

The Staying Safe Intervention

NCT03418636
View directory record Official record
Conditions
Hepatitis C, Opioid Use
Interventions
Staying Safe (Ssafe), Healthy Living
Behavioral
Lead sponsor
National Development and Research Institutes, Inc.
Other
Eligibility
18 Years to 29 Years
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 31, 2026, 3:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Preliminary Evaluation of Septin9 in Patients With Hereditary Colon Cancer Syndromes

NCT02198092
View directory record Official record
Conditions
Familial Adenomatous Polyposis, Map Syndrome, Lynch Syndrome, Hnpcc, Colorectal Cancer
Interventions
Epi proColon Testing
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 31, 2026, 3:56 AM EDT
Active, not recruiting Not applicable Interventional

Situation Awareness Incorporating Multidisciplinary Teams Reduce Arrests In the Pediatric ICU

NCT06553534
View directory record Official record
Conditions
In-hospital Cardiac Arrest, Cardiopulmonary Resuscitation
Interventions
SAMURAI PICU Bundle
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
5
States / cities
Chicago, Illinois • Akron, Ohio • Charleston, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2024 · Synced Oct 31, 2026, 3:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic (PK) Evaluation of Nalmefene Formulations

NCT07543276
View directory record Official record
Conditions
Opioid Overdose
Interventions
Nalmefene + 0.94% MgCl2, Nalmefene Hydrochloride Injection
Drug
Lead sponsor
Knoa Pharma LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 31, 2026, 3:56 AM EDT
Withdrawn Phase 2 Interventional

The Role of Antioxidant Supplementation in Keratoconus Patients

NCT02827747
View directory record Official record
Conditions
Keratoconus
Interventions
Antioxidants (Vitamins A,C,E) plus GSH, Placebo, Centrum, Dietary Sources
Other · Dietary Supplement · Combination Product
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Palm Beach Gardens, Florida
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Oct 31, 2026, 3:56 AM EDT
Terminated Phase 1 Interventional

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.

NCT05864391
View directory record Official record
Conditions
Steatohepatitis
Interventions
AZD7503
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
Chandler, Arizona • Montclair, California • Hialeah, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 31, 2026, 3:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Adaptive Stress Response: The Hot Yoga Study

NCT06395376
View directory record Official record
Conditions
Inflammation, Aging, Depression, Anxiety
Interventions
Bikram Hot Yoga Intervention, Hot Yoga Washout
Other
Lead sponsor
University of Arizona
Other
Eligibility
30 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 31, 2026, 3:56 AM EDT
Completed Phase 1 Interventional

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

NCT01226316
View directory record Official record
Conditions
Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, Tumour Response, Advanced or Metastatic Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, PIK3CA, AKT1, PTEN, ER Positive, HER2 Positive
Interventions
AZD5363
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2024
U.S. locations
12
States / cities
Los Angeles, California • Stanford, California • West Hollywood, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 31, 2026, 3:56 AM EDT
Completed Phase 1 Interventional

A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma

NCT02383368
View directory record Official record
Conditions
Lymphoma, Refractory Solid Tumors, Advanced Cancer
Interventions
ASP4132
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
New Haven, Connecticut • Chicago, Illinois • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 31, 2026, 3:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study of K0706 in Healthy Subjects

NCT03316820
View directory record Official record
Conditions
Healthy
Interventions
K0706
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated May 3, 2019 · Synced Oct 31, 2026, 3:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Soticlestat Tablets in Healthy Adults

NCT05284760
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Soticlestat
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 31, 2026, 3:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessing the Effects of a Neurobehavioral Intervention on Symptoms of Obsessive Compulsive Disorder

NCT01414023
View directory record Official record
Conditions
Obsessive Compulsive Disorder
Interventions
Cognitive Control Training, Peripheral Vision Task
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Oct 31, 2026, 3:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Low-Fat Food on Pexidartinib Pharmacokinetics in Healthy Volunteers

NCT03901313
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Treatment A - 400 mg Fasting, Treatment B - 400 mg Fed, Treatment C - 200 mg Fed
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Oct 31, 2026, 3:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of 5 and 10 mg Corplex™ Donepezil TDS Compared to 10 mg Aricept® in Healthy Volunteers

NCT04617782
View directory record Official record
Conditions
Healthy Subjects
Interventions
Donepezil TDS, Aricept
Combination Product · Drug
Lead sponsor
Corium, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 31, 2026, 3:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants

NCT06831344
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Vonoprazan ODT-1 or ODT-2 without Water, Vonoprazan ODT-1 or ODT-2 with Water, Vonoprazan (Reference)
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 31, 2026, 3:56 AM EDT
Recruiting Not applicable Interventional

Heuristic Tool To Improve Symptom Self-Management in Adolescents and Young Adults With Cancer

NCT05958316
View directory record Official record
Conditions
Symptoms and Signs, Cancer, Childhood Cancer
Interventions
Computerized Symptom Capture Tool (C-SCAT) Intervention, Usual Care Control
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
15 Years to 29 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Kansas City, Missouri • Salt Lake City, Utah • Richmond, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 31, 2026, 3:56 AM EDT
Completed Phase 1Phase 2 Interventional Results available

H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas

NCT02960230
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
Interventions
K27M peptide, Nivolumab
Biological · Drug
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
3 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
14
States / cities
San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Oct 31, 2026, 3:56 AM EDT
Recruiting Not applicable Interventional

Trial of Center-Based vs. In-Home Pivotal Response Treatment (PRT) in Autism

NCT04899544
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder, ASD
Interventions
Center-Based Pivotal Response Treatment (PRT) Intervention (PRT-C), Home-Based Pivotal Response Treatment (PRT Intervention (PRT-H)
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 5 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 31, 2026, 3:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-in-Human Study With Single and Multiple Doses of TS-161 in Healthy Participants

NCT03919409
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TS-161, TS-161 Placebo
Drug
Lead sponsor
Taisho Pharmaceutical R&D Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2020 · Synced Oct 31, 2026, 3:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult Subjects

NCT07240116
View directory record Official record
Conditions
Healthy
Interventions
Miricorilant Treatment A, Miricorilant Treatment B, Miricorilant Treatment C, Miricorilant Treatment D
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 31, 2026, 3:56 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Clinical Investigation of Eye C Better's Photobionic Intraocular Pressure Biomonitor Tonometer

NCT07762053
View directory record Official record
Conditions
Elevated Intraocular Pressure (IOP)
Interventions
Photobionic IOP Tonometer (PIB)
Device
Lead sponsor
EyeCBetter Corporation
Industry
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
La Quinta, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 31, 2026, 3:56 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Step-up to Quit: Using Low-to-moderate Intensity Exercise for Reducing Smoking Cue Reactivity Among Low-income Smokers

NCT02220465
View directory record Official record
Conditions
Sedentary Lifestyle, Cigarette Smoking
Interventions
PA+ Smoking Cessation (LMPA), Standard Care Smoking Counseling (SCC)
Behavioral
Lead sponsor
Temple University
Other
Eligibility
18 Years to 59 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Oct 31, 2026, 3:56 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

NCT05139602
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Lutikizumab, Placebo
Biological · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 31, 2026, 3:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.

NCT00942175
View directory record Official record
Conditions
Healthy
Interventions
Clopidogrel, Clopidogrel and Lansoprazole, Clopidogrel and Dexlansoprazole, Clopidogrel and Omeprazole, Clopidogrel and Esomeprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 31, 2026, 3:56 AM EDT